Event Details

CE Program/Activity
 Webinar: Restoring Vision: Retinal Implants, Gene Therapy, and the Role of Rehabilitation
Provider
Location
 Available Online - To register, visit: https://www.eventbrite.com/e/restoring-vision-retinal-implants-gene-therapy-and-the-role-of-rehabilitation-registration-49822626818
Date(s)
 November 15, 2018 - November 15, 2018 - 11/15/2018
CE Hours
 1.0
Contact Information
 technicalsupport@gaaer.org
Registration Information
 https://www.eventbrite.com/e/restoring-vision-retinal-implants-gene-therapy-and-the-role-of-rehabilitation-registration-49822626818
Fees
 Early Registration Discount is $25.00 until Oct. 31st - $35.00 thereafter
Description of CE Program/Activity
 Webinar: Restoring Vision: Retinal Implants, Gene Therapy, and the Role of Rehabilitation Join AMAC Accessibility at Georgia Tech and Georgia AER for this one-hour webinar (ACVREP CEUs and CRCs being offered). The presenter, Dr. Duane Geruschat, is a Research Associate in Ophthalmology at the Wilmer Eye Institute of the School of Medicine at Johns Hopkins University.When: Thursday, Nov. 15, 2018: 1:30pm to 2:30pm ESTWho Should Attend this Webinar?If you work with individuals who have vision loss, or have vision loss yourself and would like to learn more about the latest advancements in vision restoration, this webinar will be of value to you. This webinar will highlight the latest medical advancements in restoring vision through retinal transplants and gene therapy, and will describe the rehabilitation process accompanying such procedures.Bio of Presenter Duane R. Geruschat, Ph.D is a research associate in Ophthalmology at the Wilmer Eye Institute of the School of Medicine at Johns Hopkins University. A certified orientation and mobility specialist and low vision therapist, Dr. Geruschat studied orientation and mobility at Western Michigan University in Kalamazoo, earning a master's degree in 1976. He went on to earn a doctorate in educational psychology with a minor in vision science from Temple University in Philadelphia in 1986. His early research involved ambulation and low vision, including studies on how low vision pedestrians use their remaining vision to navigate street crossings and complex intersections. Since 2004 he worked as a member of a research team at Johns Hopkins studying various types of prosthetic vision including the Optobionics Artificial Silicon Retina (ASR) and the Argus II from Second Sight Medical Products. He was also a member of the study team at the University of Pennsylvania/Spark Therapeutics and their RPE65 gene therapy treatment designed to improve the vision of patients with lebers congenital amaurosis.